ARTreat

ARTreat targets at providing a patient-specific computational model of the cardiovascular system, used to improve the quality of prediction for the atherosclerosis progression and propagation into life-threatening events that need to be treated accordingly.

ARTreat will provide a three-level patient model describing the 3d arterial tree anatomy, the patient-specific blood flow and blood particle dynamics and the biological processes that lead to the creation and progression of atherosclerotic plaques.

ARTreat will apply the developed patient-specific model on two main applications: the clinical decision support and the training. ARTreat will produce two decision support tools to assist clinical cardiologists into providing personalized treatment selection and real-time, on- the-fly advice during invasive interventions, such stent positioning. The aim is to minimize future therapy costs, by providing higher than even possible personalized treatment support. The same patient-specific model will also be used to develop a real-case simulator training, which will support realistic hands-on skill development training to clinical cardiologists.

Finally, ARTreat is coupled with advanced clinical support tools for plaque characterization, and the discovery of new knowledge; associations among heterogeneous data, that can improve the predictive power of the patient-model. It thus supports the medical expert into programming the accumulated knowledge into the existing model and generating an adaptive patient-specific computational tool. Key market players AGFA and SORIN will exploit the ARTreat applications to provide new sophisticated solutions to their product range, while all academic and IT company partners will accumulate significant experience on the new generation patient-specific healthcare services.

For further information, please visit:
http://www.artreat.org

Project co-ordinator:
SWORD TECHNOLOGIES SA

Partners:

  • UNIVERZITET U KRAGUJEVCU
  • COMPUTER SHARING BUCURESTI SRL
  • TECHNOLOGICA EOOD
  • SAS SOFTWARE LIMITED
  • LANZA & THOMPSON INFORMATION TECHNOLOGY SRL
  • TECMIC-TECNOLOGIAS DE MICROELECTRONICA SA
  • FOUNDATION FOR RESEARCH AND TECHNOLOGY HELLAS
  • THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
  • ADVANCED SIMULATION AND DESIGN GMBH
  • UNIVERSITE PARIS DESCARTES
  • INTERCON SP. Z O.O.
  • EURO (PMS) LIMITED
  • SORIN BIOMEDICA CARDIO S.R.L.
  • AGFA HEALTHCARE N.V.
  • WORLD MATCH LIMITED
  • D.D. SYNERGY HELLAS ANONYMI EMPORIKI ETAIREIA PAROCHIS YPIRESION PLIROFORIKIS
  • CONSIGLIO NAZIONALE DELLE RICERCHE
  • UNIVERSITA DEGLI STUDI DI PARMA

Timetable: from 09/2008 –to 08/2011

Total cost: 10.520.000

EC funding: €7.650.000

Programme Acronym: FP7-ICT

Subprogramme Area: ICT-2007.5.3 Virtual physiological human

Contract type: Collaborative project (generic)

Related news article:

Most Popular Now

Significant Disparities in Telemedicine …

After "COVID-19," the term that most people will remember best from 2020 is likely to be "social distancing." While it most commonly applied to social gatherings with family and friends...

Model Used to Evaluate Lockdowns was Fla…

In a recent study, researchers from Imperial College London developed a model to assess the effect of different measures used to curb the spread of the coronavirus. However, the model...

New Virtual Screening Strategy Identifie…

A novel computational drug screening strategy combined with lab experiments suggest that pralatrexate, a chemotherapy medication originally developed to treat lymphoma, could potentially be repurposed to treat COVID-19. Haiping Zhang...

Using Artificial Intelligence to Find Ne…

Scientists have developed a machine-learning method that crunches massive amounts of data to help determine which existing medications could improve outcomes in diseases for which they are not prescribed. The intent...

FDA Releases Artificial Intelligence / M…

Today, the U.S. Food and Drug Administration released the agency's first Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. This action plan describes a multi-pronged approach...

One in Four Doctors Attacked, Harassed o…

While many physicians benefit from social media by networking with potential collaborators or interfacing with patients, a new study from Northwestern University and the University of Chicago found many physicians...

CliniSys Launches Laboratory Information…

CliniSys has launched a new laboratory information management system for genomic laboratories in the UK. The company has brought GLIMS Genomics to the UK from Europe, where it is being...

The Institute of Healthcare Management C…

The Institute of Healthcare Management has called for honest and open communication about NHS capacity after a snapshot survey revealed the scale of sickness absence across the service. The UK's leading...

First NHS Trust and Sectra Achieve Rapid…

A new region-wide approach to analysing x-rays, MRI scans, CT scans, mammography, and an entire range of crucial diagnostic images, has started to become reality, now that The Pennine Acute...

Abbott to Launch the NeuroSphere™ myPath…

Abbott (NYSE: ABT) today announced the upcoming launch of NeuroSphere™ myPath™, a digital health app designed to track and report on patient perceived pain relief and general well-being associated with...

Bayer Transforms Pharma Business through…

At its virtual Pharma Media Day, Bayer presented exciting progress in transforming its pharmaceutical business with breakthrough innovation in healthcare that will significantly help patients suffering from conditions that are...